137.31

0.76% 1.035

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $137.31, with a volume of 265.17K. It is up +0.76% in the last 24 hours and down -4.24% over the past month. Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Previous Close:

$136.28

Open:

$136.72

24h Volume:

265.17K

Relative Volume:

0.30

Market Cap:

$8.89B

Revenue:

$74.06M

Net Income/Loss:

$-114.71M

P/E Ratio:

-76.12

EPS:

-1.8039

Net Cash Flow:

$-117.90M

1W Performance:

-1.85%

1M Performance:

-4.24%

6M Performance:

+30.23%

1Y Performance:

+76.77%

1-Day Range:

$136.03

$139.11

1-Week Range:

$135.62

$152.19

52-Week Range:

$73.08

$160.81

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

132

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX Protagonist Therapeutics Inc	137.31	8.89B	74.06M	-114.71M	-117.90M	-1.8039
VRTX Vertex Pharmaceuticals Inc	509.72	129.19B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.78	94.93B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.11	82.48B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.35	53.35B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	371.37	42.01B	5.76B	514.49M	1.10B	4.4813

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-12-26	Initiated	UBS	Buy
Aug-10-26	Upgrade	Goldman	Neutral → Buy
May-21-26	Initiated	Wolfe Research	Outperform
Sep-17-25	Initiated	Barclays	Overweight
Sep-12-25	Initiated	Leerink Partners	Outperform
Jun-17-25	Initiated	Citigroup	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Dec-06-24	Initiated	Goldman	Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Sep-24-24	Initiated	TD Cowen	Buy
Sep-09-24	Initiated	Truist	Buy
Oct-30-23	Initiated	CapitalOne	Overweight
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

Oct 14, 2026

Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds - Simply Wall Street

Oct 14, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at UBS Group - MarketBeat

Oct 14, 2026

Oct 13, 2026

UBS sets USD 184.00 target for Protagonist Therapeutics stock - ad-hoc-news.de

Oct 13, 2026

Oct 12, 2026

UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target - Moomoo

Oct 12, 2026

Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha

Oct 12, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Stock Keeps "Outperform" Rating at Leerink Partners - MarketBeat

Oct 12, 2026

UBS initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com

Oct 12, 2026

Oct 10, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to "Buy" at Wall Street Zen - MarketBeat

Oct 10, 2026

Oct 08, 2026

Protagonist Therapeutics(PTGX.US) Officer Sells US$8.31 Million in Common Stock - Moomoo

Oct 02, 2026

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 58,629 Shares of Company Stock - MarketBeat

Oct 02, 2026

After exercising options, Protagonist Therapeutics (PTGX) CFO sells 58,629 shares under a trading plan. - stocktitan.net

Oct 02, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Has Consensus Price Target of $147.13 According to Analysts - MarketBeat

Oct 02, 2026

Oct 01, 2026